Literature DB >> 8583240

p53 protein and epidermal growth factor receptor expression in human astrocytomas.

R Kordek1, W Biernat, J Alwasiak, R Maculewicz, R Yanagihara, P P Liberski.   

Abstract

p53 mutations are the most frequently detected genetic alterations of gliomas, appearing in a similar proportion of low and high grade astrocytomas, while the amplification of epidermal growth factor receptor (EGFR) gene appears mainly in glioblastomas. Thus, these changes seem to delineate two subgroups of high grade astrocytomas: those originating from preexistent low grade astrocytomas and those originating de novo. Paraffin-embedded surgical specimens from 56 human astrocytomas (8 pilocytic (I.) astrocytomas, 9 low grade (II.) fibrillary astrocytomas, 9 high grade (III.) anaplastic astrocytomas and 30 glioblastomas) were analyzed immunohistochemically for the presence of p53 protein and EGFR. Approximately 41% of all cases were p53-protein-positive while 23% were EGFR-positive. Five cases (8.9%) were double-positive for p53 protein and EGFR. The p53-immunopositive nuclei were revealed in 16 cases (53.3%) of glioblastomas, 3 cases (33.3%) of high grade and 4 cases (44.4%) of low grade astrocytomas. None of pilocytic tumors was p53-positive. EGFR immunopositivity increased with the grade of malignancy (11.1%, 22.2% and 33.3%). Double EGFR-p53-positive cases occuried in similar proportions in all grades (approximately 10%) and did not show different survival rate. There were no differences between average age of patients with only-p53-positive, p53-negative (pilocytic tumors excluded) and only-EGFR-positive tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583240     DOI: 10.1007/bf01054764

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

Review 1.  Molecular cytogenetics of human neuroblastoma.

Authors:  M Schwab
Journal:  Biochim Biophys Acta       Date:  1992-09-14

2.  P53 in tumour pathology: can we trust immunocytochemistry?

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1992-04       Impact factor: 7.996

3.  Epidermal growth factor receptor in human glioma.

Authors:  N Arita; T Hayakawa; S Izumoto; T Taki; T Ohnishi; H Yamamoto; S Bitoh; H Mogami
Journal:  J Neurosurg       Date:  1989-06       Impact factor: 5.115

4.  Neoplasms of the central nervous system. Epidemiologic considerations.

Authors:  A K Percy; L R Elveback; H Okazaki; L T Kurland
Journal:  Neurology       Date:  1972-01       Impact factor: 9.910

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

Authors:  H Haapasalo; J Isola; P Sallinen; H Kalimo; H Helin; I Rantala
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

7.  Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme.

Authors:  A von Deimling; D N Louis; K von Ammon; I Petersen; T Hoell; R Y Chung; R L Martuza; D A Schoenfeld; M G Yaşargil; O D Wiestler
Journal:  J Neurosurg       Date:  1992-08       Impact factor: 5.115

8.  Distribution of p53 protein expression in gliosarcomas: an immunohistochemical study.

Authors:  S Albrecht; J H Connelly; J M Bruner
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

Authors:  D Fults; D Brockmeyer; M W Tullous; C A Pedone; R M Cawthon
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

10.  Subsets of glioblastoma multiforme defined by molecular genetic analysis.

Authors:  A von Deimling; K von Ammon; D Schoenfeld; O D Wiestler; B R Seizinger; D N Louis
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

View more
  7 in total

1.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

2.  Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study.

Authors:  G Fountzilas; A Karavelis; A Capizzello; A Kalogera-Fountzila; G Karkavelas; N Zamboglou; P Selviaridis; G Foroglou; A Tourkantonis
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables.

Authors:  Yi-Hong Zhou; Kenneth R Hess; Longjian Liu; Mark E Linskey; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

4.  EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.

Authors:  Fanny Burel-Vandenbos; Maxime Benchetrit; Catherine Miquel; Denys Fontaine; Romane Auvergne; Christine Lebrun-Frenay; Nathalie Cardot-Leccia; Jean-François Michiels; Veronique Paquis-Flucklinger; Thierry Virolle
Journal:  J Neurooncol       Date:  2010-07-24       Impact factor: 4.130

5.  Apoptosis and p53 expression in human gliomas.

Authors:  L Sipos; Z Szegedi; I Fedorcsák; D Afra; B Szende
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

6.  Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.

Authors:  X X Tian; J Y Chan; J C Pang; J Chen; J H He; T S To; S F Leung; H K Ng
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

7.  Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients.

Authors:  Mohanad Mundher Abdulghani; Mohamad Natiq Abbas; Wafaa Redha Mohammed
Journal:  Open Access Maced J Med Sci       Date:  2019-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.